Status:

COMPLETED

A Study to Find Out How BIIB141 (Omaveloxolone) Moves From the Blood Into the Breastmilk of Healthy Women Who Are Breastfeeding or Pumping Milk

Lead Sponsor:

Biogen

Conditions:

Healthy Volunteer

Eligibility:

FEMALE

18-45 years

Phase:

PHASE1

Brief Summary

In this study, researchers will learn how BIIB141, also known as omaveloxolone or SKYCLARYS®, moves through the body. This is a drug available for doctors to prescribe for patients with Friedrich's At...

Eligibility Criteria

Inclusion

  • Key
  • Lactating female 18 to 45 years of age.
  • Has given birth to an infant of at least 37 weeks' gestation.
  • Is at least 6 weeks postpartum by Day 1.
  • Body mass index at screening between 18.0 and and \< 35.0 kilograms per meter square (kg/m\^2), inclusive.
  • Is willing to discontinue breastfeeding their infant from check-in (Day -1) through 19 days after dosing.
  • Has never taken omaveloxolone.
  • Key

Exclusion

  • History of any clinically significant cardiovascular, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, dermatologic, neurologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator.
  • Clinically significant (as determined by the Investigator) 12-lead electrocardiogram (ECG) abnormalities.
  • History of, or positive test result at Screening for, human immunodeficiency virus.
  • Chronic, recurrent, or serious infection (e.g., pneumonia, septicemia), as determined by the Investigator, within 90 days prior to Screening or between Screening and Day -1.
  • Presence or history of hypotension or hypertension.
  • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Key Trial Info

Start Date :

October 18 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 8 2025

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT06612879

Start Date

October 18 2024

End Date

April 8 2025

Last Update

April 22 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Fortrea Madison WI, CRU

Madison, Wisconsin, United States, 53704

A Study to Find Out How BIIB141 (Omaveloxolone) Moves From the Blood Into the Breastmilk of Healthy Women Who Are Breastfeeding or Pumping Milk | DecenTrialz